0000899243-20-024374.txt : 20200904 0000899243-20-024374.hdr.sgml : 20200904 20200904172705 ACCESSION NUMBER: 0000899243-20-024374 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200903 FILED AS OF DATE: 20200904 DATE AS OF CHANGE: 20200904 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Roberts Christopher D. CENTRAL INDEX KEY: 0001788368 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 201162596 MAIL ADDRESS: STREET 1: C/O BLACK DIAMOND THERAPEUTICS, INC. STREET 2: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-03 0 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001788368 Roberts Christopher D. C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Scientific Officer Common Stock 2020-09-03 4 M 0 2500 10.86 A 2500 D Common Stock 2020-09-03 4 S 0 142 28.95 D 2358 D Common Stock 2020-09-03 4 S 0 2358 29.6338 D 0 D Stock Option (Right to Buy) 10.86 2020-09-03 4 M 0 2500 0.00 D 2029-09-08 Common Stock 2500 191809 D Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.035 to $30.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter. /s/ Brent Hatzis-Schoch, as Attorney-in-Fact 2020-09-04